Nastech Announces Positive Intranasal Insulin Data at American Diabetes Association Meeting
09 Junio 2008 - 6:00AM
Business Wire
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today
data from a Phase II clinical trial demonstrating that its ultra
rapid acting intranasal insulin was both superior to usual therapy
(oral anti-diabetic medicines and/or basal insulin) and
non-inferior to insulin aspart (NovoLog�), a rapid-acting
injectable insulin, in maintaining glucose control at both 60 and
90 minutes following a meal. The data also demonstrated a
statistically significant reduction in the incidence of
hypoglycemia (low blood sugar
Nastech Pharmaceutical Company (MM) (NASDAQ:NSTK)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Nastech Pharmaceutical Company (MM) (NASDAQ:NSTK)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Nastech Pharmaceutical Company (MM) (NASDAQ): 0 recent articles
Más de Nastech Pharmaceutical Company Inc. Artículos de Noticias